Solr Search

s and currently, more than 5.5 million Americans are living with this disease for which there is yet no cure yet.

ration of the philanthropist’s priorities and an understanding of the current state of research to amplify the impact of their giving.

al levels, but our understanding of gender-based health differences across U.S. states remains opaque.

alled tau—a common culprit in a number of neurodegenerative diseases—we make the case that focused strategic investment in tau research and the , At present, no disease-modifying therapies for the pure tauopathies exist. Researchers are working to develop effective therapeutic agents, which include approaches such as decreasing the amount of tau within the brain., Symptomatic Interventions At present, no disease-modifying therapies for the pure tauopathies exist.

icy evaluation, and thought leadership by convening experts and stakeholders.

ct philanthropists are poised to lead that effort like never before.    

re biomedical research ecosystem at risk.

inancial and public crises as they work to mitigate immediate needs—and the age of COVID-19 has been no different.

rain. At the time of this report, nearly 15,000 people were diagnosed with GBM each year in the United States and Europe.

h challenges for people on college campuses, and created new ones as online learning expands, key rites of passage are cancelled, and social isolation con